According to the terms of the license, Rodan + Fields Dermatologists will develop proprietary formulations for their regimen-based skincare line utilizing the new PiP3 technology with Helix’s patented peptides.
Rodan + Fields will also support the technology with clinical studies, product education for their independent sales consultants and public relations campaigns. The first of the new products is expected to be introduced in early 2009.
Lori Bush, president and general manager of Rodan + Fields Dermatologists, said: “This new technology has a broad range of potential applications in our product line and works in conjunction with a new bioactive peptide from Helix BioMedix that we are also applying in select new product initiatives.”
Stephen Beatty, president and CEO of Helix BioMedix, said: “Rodan + Fields have the ability to effectively launch and promote our technologies across a number of applications and product lines within the consumer market, further diversifying the retail offerings that include our technology.”